Ipca Labs firms up after acquisition

Image
Capital Market
Last Updated : Jan 17 2018 | 10:04 AM IST

Ipca Laboratories rose 1.63% to Rs 582.85 at 9:48 IST on BSE after the company announced acquisition of US-based Pisgah Labs Inc.

The announcement was made during trading hours today, 17 January 2018.

Meanwhile, the S&P BSE Sensex was up 58.19 points, or 0.17% to 34,829.24.

On the BSE, 11,000 shares were traded in the counter so far, compared with average daily volumes of 29,000 shares in the past two weeks. The stock had hit a high of Rs 594.70 and a low of Rs 575 so far during the day. The stock hit a 52-week high of Rs 656 on 5 April 2017. The stock hit a 52-week low of Rs 400 on 11 August 2017.

Ipca Laboratories announced the acquisition of 100% share capital of Pisgah Labs Inc., a North Carolina Corporation, Old Hendersonville Highway, Pisgah Forest, North Carolina, USA (Pisgah) by Ipca Pharmaceutical Inc., USA (the company's wholly owned subsidiary) and Onyx Scientific, UK (Onyx) (the company's wholly owned step down subsidiary) for $9.65 millions free of debt.

Pisgah Labs Inc., North Carolina, USA was originally founded in the year 1981 as a contract manufacturer and developer of active pharmaceutical ingredients (APls) and intermediates.

Pisgah Labs Inc. has been a chemistry solutions provider for over three decades and will continue to operate out of its North Carolina manufacturing facility under the Pisgah trade name. Onyx and Pisgah's capabilities in chemistry services will dovetail effectively with the company's capabilities in supporting Phase II to commercial scale programmes and also enable the company to manufacture small volume APls for US market.

For the financial year ended 30 April 2017, Pisgah had a total income of $2.89 millions and EBIDTA of $1.14 million.

Ipca Laboratories is a vertically integrated pharmaceutical company with a strong thrust on exports, which now account for nearly 47% of the company's income.

Net profit of Ipca Laboratories rose 75.56% to Rs 96.47 crore on 2.3% decline in net sales to Rs 864.29 crore in Q2 September 2017 over Q2 September 2016.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 17 2018 | 9:47 AM IST

Next Story